Production (Stage)
CASI Pharmaceuticals, Inc.
CASI
$1.33
-$0.51-27.72%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 6.24M | 13.36M | 7.79M | 3.98M | 3.41M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.24M | 13.36M | 7.79M | 3.98M | 3.41M |
| Cost of Revenue | 2.62M | 10.13M | 3.75M | 1.91M | 1.60M |
| Gross Profit | 3.62M | 3.23M | 4.05M | 2.07M | 1.81M |
| SG&A Expenses | 11.92M | 11.92M | 10.61M | 10.37M | 8.55M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -5.00K | -2.00K | -- | -- | -- |
| Total Operating Expenses | 16.47M | 25.71M | 15.88M | 13.53M | 12.63M |
| Operating Income | -10.23M | -12.35M | -8.09M | -9.55M | -9.22M |
| Income Before Tax | -10.75M | -14.37M | -8.40M | -6.96M | -9.53M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.75M | -14.37M | -8.40M | -6.96M | -9.53M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.75M | -14.37M | -8.40M | -6.96M | -9.53M |
| EBIT | -10.23M | -12.35M | -8.09M | -9.55M | -9.22M |
| EBITDA | -9.65M | -11.77M | -7.15M | -8.62M | -8.28M |
| EPS Basic | -0.69 | -0.75 | -0.55 | -0.52 | -0.71 |
| Normalized Basic EPS | -0.42 | -0.40 | -0.39 | -0.43 | -0.44 |
| EPS Diluted | -0.69 | -0.75 | -0.55 | -0.52 | -0.71 |
| Normalized Diluted EPS | -0.42 | -0.40 | -0.39 | -0.43 | -0.44 |
| Average Basic Shares Outstanding | 15.49M | 19.15M | 15.29M | 13.52M | 13.38M |
| Average Diluted Shares Outstanding | 15.49M | 19.15M | 15.29M | 13.52M | 13.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |